Health Care Down, but not by Much, Amid Deal Activity — Health Care Roundup

Health-care companies fell, but not by as much as the broad market, amid deal activity.

Health-care conglomerate Johnson & Johnson agreed to buy biotech firm Ollin Biosciences for an initial $2.2 billion payment, and has struck a deal with investment firm Blackstone to fund development of Ollin's lead eye-care product candidate.

Eli Lilly agreed to pay up to $1.5 billion to acquire Calytrix Bio, a closely held biotechnology company backed by JPMorgan that's developing treatments for a group of rare blood cancers.

 

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

November 16, 2026 17:43 ET (22:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center